Literature DB >> 23880099

Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass.

S Grassin-Delyle1, B Tremey, E Abe, M Fischler, J C Alvarez, P Devillier, S Urien.   

Abstract

BACKGROUND: Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either low- or high-dose continuous infusion schemes in adult cardiac surgery patients during cardiopulmonary bypass (CPB).
METHODS: Patients were randomized to receive either low-dose (10 mg kg(-1) followed by an infusion of 1 mg kg(-1) h(-1) throughout the operation, and 1 mg kg(-1) into the CPB) or high-dose (30 mg kg(-1), then 16 mg kg(-1) h(-1), and 2 mg kg(-1) into the CPB) TA. Serum TA concentrations were measured in 61 patients and the data were modelled using Monolix.
RESULTS: TA concentrations were 28-55 µg ml(-1) in the low-dose group and 114-209 µg ml(-1) in the high-dose group throughout surgery. TA PK was best described by a two-compartment open model. The main covariate effect was bodyweight, whereas the CPB did not influence the PK. Assuming a bodyweight of 70 kg, the population estimates were 4.8 litre h(-1) for clearance, 6.6 litre for the volume of the central compartment, 32.2 litre h(-1) for the diffusional clearance, and the peripheral volume of distribution was 10.8 litre.
CONCLUSIONS: The PK of TA was satisfactorily described by an open two-compartmental model, which was used to propose a dosing scheme suitable for obtaining and maintaining the desired plasma concentration in a stable and narrow range in cardiac surgery patients.

Entities:  

Keywords:  cardiopulmonary bypass; cardiovascular surgical procedures; pharmacokinetics; tranexamic acid

Mesh:

Substances:

Year:  2013        PMID: 23880099     DOI: 10.1093/bja/aet255

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  19 in total

Review 1.  Tranexamic acid: from trauma to routine perioperative use.

Authors:  Jeff Simmons; Robert A Sikorski; Jean-Francois Pittet
Journal:  Curr Opin Anaesthesiol       Date:  2015-04       Impact factor: 2.706

2.  Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery.

Authors:  Ralph Gertler; Michael Gruber; Stanislas Grassin-Delyle; Saïk Urien; Klaus Martin; Peter Tassani-Prell; Siegmund Braun; Simon Burg; Gunther Wiesner
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

3.  Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.

Authors:  Jia Shi; Chenghui Zhou; Wei Pan; Hansong Sun; Sheng Liu; Wei Feng; Weijian Wang; Zhaoyun Cheng; Yang Wang; Zhe Zheng
Journal:  JAMA       Date:  2022-07-26       Impact factor: 157.335

4.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

5.  Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study.

Authors:  Julien Lanoiselée; Paul J Zufferey; Edouard Ollier; Sophie Hodin; Xavier Delavenne
Journal:  Br J Clin Pharmacol       Date:  2017-11-28       Impact factor: 4.335

6.  Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery.

Authors:  Shuhui Li; Homa K Ahmadzia; Dong Guo; Elyes Dahmane; Adam Miszta; Naomi L C Luban; Jeffrey S Berger; Andra H James; Alisa S Wolberg; John N van den Anker; Jogarao V S Gobburu
Journal:  Br J Clin Pharmacol       Date:  2021-03-08       Impact factor: 4.335

7.  Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women.

Authors:  Homa K Ahmadzia; Naomi L C Luban; Shuhui Li; Dong Guo; Adam Miszta; Jogarao V S Gobburu; Jeffrey S Berger; Andra H James; Alisa S Wolberg; John van den Anker
Journal:  Am J Obstet Gynecol       Date:  2020-11-26       Impact factor: 10.693

8.  Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement.

Authors:  Aránzazu González Osuna; Luisa Fernanda Rojas; Claudia Lamas; Xavier Aguilera Roig; Francesc Pla-Junca; Sebastián Videla; Mª José Martínez-Zapata; Marta Valle
Journal:  Clin Pharmacokinet       Date:  2021-07-13       Impact factor: 6.447

9.  Physiologically based modelling of tranexamic acid pharmacokinetics following intravenous, intramuscular, sub-cutaneous and oral administration in healthy volunteers.

Authors:  Zoe Kane; Roberto Picetti; Alison Wilby; Joseph F Standing; Stanislas Grassin-Delyle; Ian Roberts; Haleema Shakur-Still
Journal:  Eur J Pharm Sci       Date:  2021-06-01       Impact factor: 4.384

10.  High- versus low-dose tranexamic acid as part of a Patient Blood Management strategy for reducing blood loss in patients undergoing surgery for adolescent idiopathic scoliosis.

Authors:  Sundeep Tumber; Adam Bacon; Casey Stondell; Sampaguita Tafoya; Sandra L Taylor; Yashar Javidan; Eric Klineberg; Rolando Roberto
Journal:  Spine Deform       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.